Wells Fargo analyst Derek Archila raised the firm’s price target on Disc Medicine (IRON) to $79 from $78 and keeps an Overweight rating on the shares. The firm believes there is a good chance Disc Medicine can resolve bitopertin’s complete response letter with the ongoing Phase 3 APOLLO trial and that the outcome of the upcoming Type A meeting will provide that clarity. Wells is positively biased into the update which is likely in mid-to-late April.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine Implements Restructuring Following FDA Response
- Disc Medicine price target lowered to $83 from $114 at Truist
- Disc Medicine price target raised to $111 from $110 at Stifel
- Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
- Disc Medicine: Strong Cash Runway and Bitopertin Upside Support Buy Rating Despite Regulatory Setbacks